2022-10-31-CBInsights-数字健康状况2022年第3季度报告（英）_145页_4mb

Overall, digital health investments experienced a significant downturn in Q3 2022, marked by declining funding and deal volumes globally. The quarter saw a historic low in both metrics since Q1 2019, with a sharp QoQ drop in funding (-37%) and deals (-44%).

Across regions, while the US continued to dominate in terms of deal volume and early-stage focus, Asia, Europe, and others all saw declines, with Asia facing the most significant quarterly drop in funding since Q3 2020. Deal sizes across early, mid, and late-stage rounds also contracted compared to prior years in most regions except India.

Despite the challenging climate, certain segments showed notable growth:

• Asia led in mega-round funding during Q3.
• Europe saw a slight rebound in unicorn valuation.
• Later-stage financings slightly outpaced early-stage in deal volume globally.
• US venture capital activity showed resilience in the third quarter.

Digital health investors and companies continue to navigate a complex landscape characterized by reduced capital availability, increased scrutiny, and ongoing transformation driven by consolidation, product innovation, and adoption pressures. Sectors like digital therapeutics, mental health tech, and health IT showed slight upticks but remain in long-term downward trends. Key players and investment hubs, particularly in the US and select Asia-Pacific markets, continue to drive activity, though at significantly reduced levels compared to pre-pandemic years.